Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
R/S approved by management with a view to list on senior exchange
Ratio approved - one for two. TO one for 15 - whichever is appropriate for uplisting
Time for r/s - upto 1 year
Look at Novartis deal with XNCR -$2.4B
Xnc is in the same space as MBVX - mAB - they have engineered platform and mb has fully humanized AB
Hope someone looks at mb and its stack of mAB
Any updates on the potential JUNO partnership ?
If you look at ASCO - there were many drugs from BP were mAB
So in my view MBVX is sitting on huge IP and range of mAB that are best in class.
However they all are in pre-clinical which means - years away from any meaningful progress in P1 or P2
Also with lack of funds - they cannot do simultaneous progress.
The best thing that can happen is good partnership or just plain BO - with current market cap 18.6 million - any BP CAN throw 100-200 million for IP - that can turn this into 5-10 bagger.
nice move, needs volume...
MBVX - Where's the bottom?
Can't keep falling forever, right?
IMO ego and greed....gets in the way when the darts land right every 20th throw at stock symbols
copy paste from a stock website is not DD
My guess is he's gone the membership route because by broadcasting his picks in the open he's opened himself to a whole whack of shorts jumping on his picks.
Comical that he sells a "membership."
Yea, LOL, no problem, i he front loads the info to paid subs before he buys!!! And then put a 5% stoplimt
You need to subscribe for that info.
I got out a while ago, hope you did as well. Hope it goes up for those still in!!
Another 7% RED day here. Must be nice making money following JBEM alerts IMO.
NOT. LMFAOOO.
Lmao. This "pick" is very special. Tanks 5% every day. All that time supposedly spent on DD and this is the junk that comes out of it? Lmao.
Bag holders galore here IMO.
I just hit reply, wasn't asking you directly, sorry sir..
seems its ok to put out opinions, copy/pasted material, on stocks, but we never see DD when a stock price goes to tank..
both should be covered,IMO..
I'm not exactly sure what you are asking?
Where is the DD on downturn of PPS?
You seem to be correct. No volume here.
America's Antibody Congress in San Diego on May 19-20, 2016.
Come and gone...nobody interested from the presentation I reckon..?
probably bailed long ago...
stick to darts , its free (except the darts and board)
MBVX has great mAB access but does not financial muscle to test them.
If you see ASCO abstracts - there are so many cancer drugs on trial using mAB
The value of this co is in the IP it owns than the trials - I hope some BP notices them and buys them for decent price.
Only 3k annually to still get front run.
Its easier to fool folks, than to convince them they been fooled...
is this dilution?
http://ih.advfn.com/p.php?pid=nmona&article=71509285&symbol=MBVX
a membership? ROFLOL
From dart throwing and luck? 50%? That a HUGE HUGE hit, and bet that guy long gone, not a word about MabVax since beginning. Reality will settle in. The presentations hurt IMO
Should run for politics..crazy
Make that down over 50% now. And this guy wants to sell a membership?
Loser, who was interested in the last presentation?
Steadily down since those days, right?
3, THREE, presentations
Todays news and RED? almost another 5%
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
8:00 am ET May 16, 2016
down about 30% since recommend?
how many is this?
Thank you Jbem for all your amazing picks and help!! Thanks for your email reply when convenient! You rock!!! Thank you!! : )
I'll get back to you shortly. Thanks for your support.
10-k says they have 5.6 million in cash and cash equivalents. So, not yet I think.
Jbem-- Thanks for all your great picks! I sent you an email with a question two days ago and I would love your reply when convenient! Thanks so much!! : )
yep , big time, and don't they need money?
52-Wk Range
0.41 - 2.82
LowHigh
Possible. Nasty day all around though
Link to Jbem's extensive MBVX DD...great info here.
https://groups.google.com/forum/#!category-topic/jbem777/DD/Y9j-cUBUXCA
MBVX Chart perhaps we see a steady climb up now as the second 1/2 of 2016 nears... lots to look forward to as this one plays out imo.
Interim data from recently initiated pancreatic cancer trials is expected in mid-2016 (Q2/Q3) with final data readouts at the end of 2016. Data from their Sarcoma and Ovarian cancer vaccine programs, licensed from the renowned Memorial Sloan Kettering Cancer Center, are also expected to be released later in 2016. Furthermore, the company has initiated an option agreement in which Juno Therapeutics (JUNO) is utilizing their technology and patents to explore possible treatment indications. The agreement with Juno requires a response from Juno by June 30th, 2016 and if a partnership is formed it would likely contain license fees, milestone payments, and royalty-based compensation.
I am in at .78 and holding tight at the moment.
Yep I bought at .84 and am just going to sit on this. Why sell at lows?
If you want liquidity then raise the bid. Owners of this stock are confident in the near future for big gains. I know that I am not letting go of any of my shares at these prices.
Jesus, liquidity on this ticker is non existent
old and fat timers...
Yes you have to sit on the bid and "stick your finger out" thats a term we old timers use when trying to buy or sell otcbb stocks... that .001 extra can make the difference...
Good add. Tough to add
I added more @.682...stupid number but it worked..eom
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1194
|
Created
|
04/12/01
|
Type
|
Free
|
Moderators |
| MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. We generate our pipeline of antibody-based product candidates from patients who have been vaccinated with propriety vaccines licensed from Memorial Sloan-Kettering Cancer Center, or MSKCC. Our approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform. Our approach to antibody discovery is to seek to identify the antibody candidates with superior performance characteristics while minimizing many of the toxicity and off target binding drawbacks of other discovery technologies. Our lead antibody candidates have been recovered from patients who had substantially better treatment outcomes than almost all other patients in clinical trials we conducted or that were conducted by our partners. Our therapeutic vaccines were developed at MSKCC and are exclusively licensed to us pursuant to agreements with MSKCC in 2008. These vaccines are administered in the adjuvant (period following conventional treatment consisting of watchful waiting) setting and have shown in clinical studies to elicit a protective antibody response. The antibodies are intended to seek out circulating tumor cells and micrometastases (small clusters of cancer cells) to kill them before they can cause cancer recurrence. Our lead cancer vaccines targeting recurrent sarcoma (soft tissue cancer) and ovarian cancer are currently in proof of concept Phase II multi-center clinical trials. Both trials have received substantial federal grant monies to support their development. A vaccine to address the orphan disease neuroblastoma (cancer starting in the adrenal gland of children which may spread to nervous tissue and bone marrow) has completed an initial Phase I trial at MSKCC and is expected be ready for a Phase II trial by early 2015. MSKCC and the Company have completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, and small cell lung cancer over the last three years.MBVX Intraday Stock Chart
My Stocks Activity For MBVX
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |